Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis partner GSK reports positive Phase 3 data for hepatitis B drug; FDA decision due Q3 2026
Filed May 28, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
high
GSK's Phase 3 trials for bepirovirsen met primary endpoints with 19% functional cure rate vs 0% placebo in chronic hepatitis B patients—far exceeding current standard of care (<1% cure rate).
Item 8.01 verify on EDGAR → -
high
In patient subgroup representing 45% of global CHB cases, bepirovirsen expected to achieve 26% functional cure rate. FDA decision expected Q3 2026; drug has Breakthrough and Fast Track designations.
Item 8.01 verify on EDGAR → -
high
Ionis eligible for additional regulatory and sales milestones plus 10-12% tiered royalties on net sales. Has already received upfront, license, and development milestone payments from GSK.
Item 8.01 verify on EDGAR → -
medium
Safety profile acceptable with most common side effects being injection site reactions and temporary liver enzyme elevation. GSK preparing for commercial launch.
Item 8.01 verify on EDGAR →
Summary
Ionis Pharmaceuticals announced that its partner GSK reported successful Phase 3 trial results for bepirovirsen, an investigational antisense drug for chronic hepatitis B. The pooled data from two pivotal trials showed a 19% functional cure rate compared to 0% for placebo, representing a dramatic improvement over current treatments which achieve functional cure in less than 1% of patients.
In a key patient subgroup with lower disease markers—representing roughly 45% of diagnosed cases worldwide—the cure rate expected to reach 26%. For Ionis shareholders, this represents a significant near-term catalyst. The drug is under priority review by the FDA with Breakthrough and Fast Track designations, and GSK expects the first regulatory decision in Q3 2026.
Approval would trigger additional milestone payments to Ionis and establish a royalty stream of 10-12% on net sales. With GSK already preparing for commercial launch, this partnered asset could become a meaningful revenue contributor. Investors should watch for the FDA decision in Q3 2026 and any subsequent regulatory approvals in Europe, Japan, and China where the drug is also under review. The commercial launch timeline and initial sales uptake will determine the magnitude of Ionis's royalty revenue from this program.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Ionis partner GSK reported positive pivotal data for bepirovirsen, an investigational ASO for chronic hepatitis B treatment.
Added in current filing · verify on EDGAR →
On May 28, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) issued a press release announcing that its partner, GSK, reported positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (“ASO”) for the treatment of chronic hepatitis B (“CHB”).
Ionis disclosed that its partner GSK reported positive pivotal trial data for bepirovirsen, an investigational antisense drug candidate for chronic hepatitis B. Pivotal data typically refers to Phase 3 trial results that can support regulatory approval. This is a material development for a partnered asset that could generate future royalties or milestone payments for Ionis.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In a key secondary endpoint, a functional cure rate of 26% (200 of 768 vs. 0 of 393 in the placebo group, with p<0.001 in both trials) was achieved in participants with ≤1000 IU/ml HBsAg level, a group that represents approximately 45% of diagnosed CHB cases globally.
In a patient subgroup with lower baseline HBsAg levels (≤1000 IU/ml), which represents about 45% of diagnosed chronic hepatitis B cases globally, bepirovirsen achieved an even higher 26% functional cure rate versus 0% for placebo. This suggests the drug may be particularly effective in a substantial portion of the target patient population.
Added in current filing · verify on EDGAR →
Bepirovirsen is currently under priority review by the U.S. Food and Drug Administration (FDA) with both Breakthrough and Fast Track Designation. It is also under review by regulatory authorities in Europe, Japan with SENKU designation and China with Breakthrough Therapy and Priority Review designation. GSK anticipates the first regulatory decisions in Q3 2026 and launch preparations are underway.
Bepirovirsen has received priority designations from multiple regulatory agencies including FDA Breakthrough and Fast Track status, and similar expedited review designations in Japan and China. GSK expects the first regulatory decisions in Q3 2026 and is preparing for commercial launch, indicating potential near-term revenue opportunity.
Added in current filing · verify on EDGAR →
The trials showed an acceptable safety and tolerability profile consistent with other studies of bepirovirsen. The three most frequently observed adverse events were injection site erythema, local pain and temporary rise in the blood level of a liver enzyme.
The Phase 3 trials demonstrated an acceptable safety profile with the most common adverse events being injection site reactions and temporary liver enzyme elevation. This favorable safety profile supports the drug's regulatory approval prospects and commercial viability.
Event · Item 9.01 — Financial Statements and Exhibits
Ionis Pharmaceuticals filed an 8-K attaching a press release dated May 28, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated May 28, 2026.
The 8-K attaches a press release dated May 28, 2026 as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature of the announcement cannot be determined from this 8-K alone. Investors should review the attached exhibit for details.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify